Ignite Creation Date:
2025-12-24 @ 3:06 PM
Ignite Modification Date:
2025-12-29 @ 5:30 AM
Study NCT ID:
NCT04788459
Status:
TERMINATED
Last Update Posted:
2023-03-29
First Post:
2021-03-01
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000086382', 'term': 'COVID-19'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D012141', 'term': 'Respiratory Tract Infections'}], 'ancestors': [{'id': 'D011024', 'term': 'Pneumonia, Viral'}, {'id': 'D011014', 'term': 'Pneumonia'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D018352', 'term': 'Coronavirus Infections'}, {'id': 'D003333', 'term': 'Coronaviridae Infections'}, {'id': 'D030341', 'term': 'Nidovirales Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1', 'PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'PREVENTION', 'interventionModel': 'SEQUENTIAL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 68}}, 'statusModule': {'whyStopped': 'The good progress of the Italian national vaccination campaign against COVID-19 made impossible to complete the study as planned.', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2021-02-25', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2021-12', 'completionDateStruct': {'date': '2021-12-07', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-03-28', 'studyFirstSubmitDate': '2021-03-01', 'studyFirstSubmitQcDate': '2021-03-05', 'lastUpdatePostDateStruct': {'date': '2023-03-29', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2021-03-09', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2021-12-07', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence of solicited local Adverse events (AEs) at the injection site (for Phase 1)', 'timeFrame': 'Through 7 days post-each vaccination'}, {'measure': 'Incidence of solicited systemic AEs (for Phase 1)', 'timeFrame': 'Through 7 days post-each vaccination'}, {'measure': 'Incidence of unsolicited AEs (for Phase 1)', 'timeFrame': 'through 4 weeks post-each vaccination'}, {'measure': 'White Blood Cell (WBC) levels (for Phase 1)', 'timeFrame': 'through 4 weeks post-each vaccination', 'description': 'Change from baseline at specific timepoints'}, {'measure': 'Red Blood Cell (RBC) levels (for Phase 1)', 'timeFrame': 'through 4 weeks post-each vaccination', 'description': 'Change from baseline at specific timepoints'}, {'measure': 'Platelets levels (for Phase 1)', 'timeFrame': 'through 4 weeks post-each vaccination', 'description': 'Change from baseline at specific timepoints'}, {'measure': 'Alanine Transaminase (ALT) levels (for Phase 1)', 'timeFrame': 'through 4 weeks post-each vaccination', 'description': 'Change from baseline at specific timepoints'}, {'measure': 'Aspartate Transaminase (AST) levels (for Phase 1)', 'timeFrame': 'through 4 weeks post-each vaccination', 'description': 'Change from baseline at specific timepoints'}, {'measure': 'Creatine Phosphokinase (CPK) levels (for Phase 1)', 'timeFrame': 'through 4 weeks post-each vaccination', 'description': 'Change from baseline at specific timepoints'}, {'measure': 'Quantitative antibody titers, binding to the specific SARS-CoV-2 antigen (for Phase 2)', 'timeFrame': 'through 4 weeks post-last vaccination', 'description': 'Geometric Mean Titer (GMT) and Geometric Mean Fold Rise (GMFR) from baseline'}, {'measure': 'SARS-CoV-2 neutralizing antibody titer (for Phase 2)', 'timeFrame': 'through 4 weeks post-last vaccination', 'description': 'GMT and GMFR from baseline'}, {'measure': 'Change from baseline in antigen-specific cellular immune responses to SARS-CoV-2 (for Phase 2)', 'timeFrame': 'through 4 weeks post-last vaccination', 'description': 'Interferon-gamma (IFN-γ) ELISpot'}, {'measure': 'Percentage of subjects who seroconverted (for Phase 2)', 'timeFrame': 'through 4 weeks post-last vaccination'}], 'secondaryOutcomes': [{'measure': 'Quantitative antibody titers, binding to the specific SARS-CoV-2 antigen (for Phase 1)', 'timeFrame': 'through 4 weeks post-last vaccination', 'description': 'GMT and GMFR from baseline'}, {'measure': 'SARS-CoV-2 neutralizing antibody titer (for Phase 1)', 'timeFrame': 'through 4 weeks post-last vaccination', 'description': 'GMT and GMFR from baseline'}, {'measure': 'Change from baseline in antigen-specific cellular immune responses to SARS-CoV-2 (for Phase 1)', 'timeFrame': 'through 4 weeks post-last vaccination', 'description': 'Interferon-gamma (IFN-γ) ELISpot'}, {'measure': 'Percentage of subjects who seroconverted (for Phase 1)', 'timeFrame': 'through 4 weeks post-last vaccination'}, {'measure': 'Incidence of unsolicited AEs (for Phase 1)', 'timeFrame': 'through study completion (6 months)'}, {'measure': 'Incidence of solicited local AEs at the injection site (for Phase 2)', 'timeFrame': 'Through 7 days post-each vaccination'}, {'measure': 'Incidence of solicited systemic AEs (for Phase 2)', 'timeFrame': 'Through 7 days post-each vaccination'}, {'measure': 'Incidence of unsolicited AEs (for Phase 2)', 'timeFrame': 'through 4 weeks post-each vaccination'}, {'measure': 'White Blood Cell (WBC) levels (for Phase 2)', 'timeFrame': 'through 4 weeks post-each vaccination', 'description': 'Change from baseline at specific timepoints'}, {'measure': 'Red Blood Cell (RBC) levels (for Phase 2)', 'timeFrame': 'through 4 weeks post-each vaccination', 'description': 'Change from baseline at specific timepoints'}, {'measure': 'Platelets levels (for Phase 2)', 'timeFrame': 'through 4 weeks post-each vaccination', 'description': 'Change from baseline at specific timepoints'}, {'measure': 'Alanine Transaminase (ALT) levels (for Phase 2)', 'timeFrame': 'through 4 weeks post-each vaccination', 'description': 'Change from baseline at specific timepoints'}, {'measure': 'Aspartate Transaminase (AST) levels (for Phase 2)', 'timeFrame': 'through 4 weeks post-each vaccination', 'description': 'Change from baseline at specific timepoints'}, {'measure': 'Creatine Phosphokinase (CPK) levels (for Phase 2)', 'timeFrame': 'through 4 weeks post-each vaccination', 'description': 'Change from baseline at specific timepoints'}, {'measure': 'Incidence of unsolicited AEs (for Phase 2)', 'timeFrame': 'through study completion (6 months)'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Infections Viral', 'Coronavirus Disease 2019', 'Respiratory Tract Infections', 'Vaccine', 'SARS-COV-2'], 'conditions': ['COVID-19', 'Protection Against COVID-19 and Infections With SARS-CoV- 2', 'COVID-19 Immunisation']}, 'descriptionModule': {'briefSummary': 'This is a multicentre, open-label Phase 1/2 study, with a first-in-human (FIH) dose escalation part (Phase 1 study) followed by an open-label single arm (or two-arms, randomized) dose expansion part (Phase 2 study). The vaccine will be administered by intramuscular (IM) injection followed by electroporation (EP) applied to the injection site.\n\nThe study is aimed at assessing the safety and immunogenicity of COVID-eVax, a DNA plasmid-based vaccine whose target antigen is a portion of the S protein of SARS-CoV-2 virus (the Receptor Binding Domain located in the CTD1 of the S1 region of the S protein).\n\nIn animal models COVID-eVax was safe and induced high immunological humoral and cellular response.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Signed and dated informed consent obtained before undergoing any study-specific procedure\n2. Healthy male or female aged ≥18 and ≤ 65 years\n3. Body Mass Index \\>18.5 and ≤30 kg/m2\n4. Vital signs within the following values or ranges:\n\n 1. Body temperature ≤ 37,5 °C\n 2. Pulse frequency ≥51 and ≤100 beats per minute\n 3. Diastolic BP ≥60 mmHg, ≤ 90 mmHg\n 4. Systolic BP ≥ 90 mmHg, ≤ 140 mmHg\n 5. Respiratory rate ≥ 12 breaths per minute, ≤ 16 breaths per minute\n5. ECG at screening normal or with no clinically significant findings (pre-excitation syndromes, e.g., Wolff-Parkinson-White syndrome are absolute exclusion criteria)\n6. Laboratory examinations within normal reference range or with no clinically significant abnormalities\n7. Absence of any respiratory and flu-like symptoms\n8. Non-pregnant women of childbearing potential, willing to practice a highly effective method of contraception from enrolment up to study completion or at least 90 days after the last vaccination in case of withdrawal\n9. For sexually active men with a female partner of childbearing potential, willingness to use a condom and to refrain from donating sperm from enrolment up to study completion or at least 90 days after the last vaccination in case of withdrawal\n10. Agreement to refrain from blood donation during the course of the study\n11. Able and willing to comply with all study procedures.\n\nExclusion Criteria:\n\n1. History of confirmed infection with SARS-CoV-2, by positive nasopharyngeal swab or by positive serological test for SARS-CoV-2 antibodies\n2. Positive serological test for SARS-CoV-2 antibodies at screening\n3. Subjects at high risk of SARS-CoV-2 infection prior or during the trial, including:\n\n 1. subjects with any known exposure in the 4 weeks before enrolment\n 2. close contacts of suspected or confirmed COVID-19 or SARS-CoV-2 infection cases\n 3. subjects quarantined for any reason\n 4. frontline healthcare professionals working in Emergency departments, ICU and other higher risk healthcare areas\n4. Positive serological tests for:\n\n 1. Hepatitis B surface antigen (HBsAg)\n 2. Hepatitis C antibodies\n 3. Human Immunodeficiency Virus (HIV) antibodies\n5. Subjects with any of the following specific contraindications, even in medical history:\n\n 1. Type 2 diabetes or glucose intolerance, even if controlled\n 2. Hypertension, even if controlled\n 3. chronic obstructive pulmonary disease (COPD)\n 4. Any cardiac disease, even if not evident at ECG\n 5. Pacemaker\n6. Use of any investigational drugs/treatments, or enrolment in a clinical trial during the 6 months preceding screening\n7. Prior administration of any vaccine in the 2 weeks preceding screening\n8. Administration of any monoclonal or polyclonal antibody product within 4 weeks preceding screening\n9. Administration of any blood product within 3 months of screening\n10. Current or prior administration, within the 6 months preceding screening, of immunosuppressants (inhaled, topical skin and/or eye drop-containing corticosteroids; a short course of corticosteroids, defined as ≤20 mg/day prednisone or equivalent for 10 days, and low-dose methotrexate are allowed until 4 weeks prior to screening)\n11. Any prior major surgery or any chemo- or radiation therapy within 5 years of screening\n12. Current or suspected immunosuppressive or immunodeficient state, including HIV infection, asplenia, recurrent severe infections\n13. Active, known, or suspected autoimmune disease (except mild psoriasis, well-controlled autoimmune thyroid disease, vitiligo or stable coeliac disease not requiring immunosuppressive or immunomodulatory therapy)\n14. Bleeding disorders (e.g. coagulopathy or platelet disorder or coagulation factor deficiency) or prior history of significant bleeding or bruising following IM injections or venipuncture\n15. History of seizures or mental illness\n16. History of allergy to vaccines or of severe allergic reaction of any kind\n17. Metal implants within 20 cm of the planned site(s) of injection\n18. Presence of keloid scar formation or hypertrophic scar, or other clinically significant medical condition at the planned site(s) of injection\n19. Any abnormality or permanent body art (e.g. tattoos) that would interfere with the ability to observe local reactions at the injection site in the deltoid area\n20. History of alcohol or drug abuse during the 12 months preceding the screening\n21. Pregnancy (i.e. positive pregnancy test) or willingness/intention to become pregnant during the study\n22. Breastfeeding\n23. Any other clinically relevant disease and condition that, in the opinion of the Investigator, may jeopardize efficacy or safety assessments or may compromise the subject's safety during trial participation."}, 'identificationModule': {'nctId': 'NCT04788459', 'briefTitle': 'Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers', 'organization': {'class': 'INDUSTRY', 'fullName': 'Takis'}, 'officialTitle': 'A Phase I/II Study to Assess the Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers', 'orgStudyIdInfo': {'id': 'COV-1/2-01'}, 'secondaryIdInfos': [{'id': '2020-003734-20', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': '0.5 mg PB', 'description': '0.5 mg PB (Prime-Boost, 4 weeks apart) - Total dose: 1 mg\n\nIM injection + electroporation by IGEA Cliniporator® and EPSGun, on Day 1 and Day 29', 'interventionNames': ['Biological: COVID-eVax', 'Device: Cliniporator® and EPSGun']}, {'type': 'EXPERIMENTAL', 'label': '1 mg PB', 'description': '1 mg PB (Prime-Boost, 4 weeks apart) - Total dose: 2 mg\n\nIM injection + electroporation by IGEA Cliniporator® and EPSGun, on Day 1 and Day 29', 'interventionNames': ['Biological: COVID-eVax', 'Device: Cliniporator® and EPSGun']}, {'type': 'EXPERIMENTAL', 'label': '2 mg PB', 'description': '2 mg PB (Prime-Boost, 4 weeks apart) - Total dose: 4 mg\n\nIM injection + electroporation by IGEA Cliniporator® and EPSGun, on Day 1 and Day 29', 'interventionNames': ['Biological: COVID-eVax', 'Device: Cliniporator® and EPSGun']}, {'type': 'EXPERIMENTAL', 'label': '2 mg P', 'description': '2 mg P (Prime) - Total dose: 2 mg\n\nIM injection + electroporation by IGEA Cliniporator® and EPSGun, on Day 1', 'interventionNames': ['Biological: COVID-eVax', 'Device: Cliniporator® and EPSGun']}], 'interventions': [{'name': 'COVID-eVax', 'type': 'BIOLOGICAL', 'description': 'Plasmid DNA Vaccine for COVID-19', 'armGroupLabels': ['0.5 mg PB', '1 mg PB', '2 mg P', '2 mg PB']}, {'name': 'Cliniporator® and EPSGun', 'type': 'DEVICE', 'description': 'IGEA Electroporation Device', 'armGroupLabels': ['0.5 mg PB', '1 mg PB', '2 mg P', '2 mg PB']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Monza', 'country': 'Italy', 'facility': 'San Gerardo Hospital', 'geoPoint': {'lat': 45.58005, 'lon': 9.27246}}, {'city': 'Naples', 'country': 'Italy', 'facility': 'Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale', 'geoPoint': {'lat': 40.85216, 'lon': 14.26811}}, {'city': 'Rome', 'country': 'Italy', 'facility': 'INMI Lazzaro Spallanzani', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'city': 'Verona', 'country': 'Italy', 'facility': '- CRC Centro Ricerche Cliniche di Verona', 'geoPoint': {'lat': 45.43854, 'lon': 10.9938}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Takis', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Rottapharm Biotech', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}